Trial Search Results

A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations

This study is designed to evaluate the preliminary anti-tumor activity and tolerability of PF-03084014 when administered as a single agent in the treatment of patients with advanced triple receptor-negative breast cancer (mTNBC) harboring genomic alterations in Notch receptors (NA+), and in a smaller subset of mTNBC patients whose tumor tests negative for genomic alterations in Notch receptors (NA-)

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Pfizer

Stanford Investigator(s):

Intervention(s):

  • Drug: PF-03084014
  • Drug: PF-03084014
  • Drug: PF-03084014

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - Histological or cytological diagnosis of triple negative breast cancer (TNBC) with
   evidence of a) metastatic or b) locally recurrent advanced disease that is not
   amenable to resection or radiotherapy with curative intent.

   - Availability of an original diagnostic tumor tissue or the most recent metastatic
   tumor biopsies (archival biopsy or de novo biopsy) and a peripheral blood sample for
   Notch receptors genomic profiling

Exclusion Criteria:

   - Known brain metastases.

   - Prior treatment with gamma secretase inhibitor or other Notch signaling inhibitor.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Female

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting